CD38 and Miyoshi myopathy: Currently, two anti-CD38 monoclonal antibodies, daratumumab and isatuximab, are approved for MM in the clinic [85,86,87,88], whilst a third, MOR 202, is presently being evaluated in clinical trials [11].